Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Identifying Important Outcomes for Young People With CKD and Their Caregivers: A Nominal Group Technique Study.

Hanson CS, Gutman T, Craig JC, Bernays S, Raman G, Zhang Y, James LJ, Ralph AF, Ju A, Manera KE, Teixeira-Pinto A, Viecelli AK, Alexander SI, Blydt-Hansen TD, Dionne J, McTaggart S, Michael M, Walker A, Carter S, Wenderfer SE, Winkelmayer WC, Bockenhauer D, Dart A, Eddy AA, Furth SL, Gipson DS, Goldstein SL, Groothoff J, Samuel S, Sinha A, Webb NJA, Yap HK, Zappitelli M, Currier H, Tong A.

Am J Kidney Dis. 2019 Mar 15. pii: S0272-6386(19)30086-1. doi: 10.1053/j.ajkd.2018.12.040. [Epub ahead of print]

PMID:
30885704
2.

Drug-induced tubulointerstitial nephritis: hypersensitivity and necroinflammatory pathways.

Eddy AA.

Pediatr Nephrol. 2019 Feb 28. doi: 10.1007/s00467-019-04207-9. [Epub ahead of print] Review.

PMID:
30820701
3.

Child and Parental Perspectives on Communication and Decision Making in Pediatric CKD: A Focus Group Study.

Gutman T, Hanson CS, Bernays S, Craig JC, Sinha A, Dart A, Eddy AA, Gipson DS, Bockenhauer D, Yap HK, Groothoff J, Zappitelli M, Webb NJA, Alexander SI, Goldstein SL, Furth S, Samuel S, Blydt-Hansen T, Dionne J, Michael M, Wenderfer SE, Winkelmayer WC, Currier H, McTaggart S, Walker A, Ralph AF, Ju A, James LJ, Carter S, Tong A.

Am J Kidney Dis. 2018 Oct;72(4):547-559. doi: 10.1053/j.ajkd.2018.05.005. Epub 2018 Jul 3.

PMID:
29980375
4.

Uromodulin deficiency alters tubular injury and interstitial inflammation but not fibrosis in experimental obstructive nephropathy.

Maydan O, McDade PG, Liu Y, Wu XR, Matsell DG, Eddy AA.

Physiol Rep. 2018 Mar;6(6):e13654. doi: 10.14814/phy2.13654.

5.

Range and Heterogeneity of Outcomes in Randomized Trials of Pediatric Chronic Kidney Disease.

Chong LSH, Sautenet B, Tong A, Hanson CS, Samuel S, Zappitelli M, Dart A, Furth S, Eddy AA, Groothoff J, Webb NJA, Yap HK, Bockenhauer D, Sinha A, Alexander SI, Goldstein SL, Gipson DS, Raman G, Craig JC.

J Pediatr. 2017 Jul;186:110-117.e11. doi: 10.1016/j.jpeds.2017.03.034. Epub 2017 Apr 24.

PMID:
28449820
6.

The impact of small kidneys.

Matsell DG, Cojocaru D, Matsell EW, Eddy AA.

Pediatr Nephrol. 2015 Sep;30(9):1501-9. doi: 10.1007/s00467-015-3079-5. Epub 2015 Mar 21.

PMID:
25794549
7.

Overview of the cellular and molecular basis of kidney fibrosis.

Eddy AA.

Kidney Int Suppl (2011). 2014 Nov;4(1):2-8. Review.

8.

Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD.

Okamura DM, Bahrami NM, Ren S, Pasichnyk K, Williams JM, Gangoiti JA, Lopez-Guisa JM, Yamaguchi I, Barshop BA, Duffield JS, Eddy AA.

J Am Soc Nephrol. 2014 Jan;25(1):43-54. doi: 10.1681/ASN.2012090962. Epub 2013 Sep 5.

9.

The origin of scar-forming kidney myofibroblasts.

Eddy AA.

Nat Med. 2013 Aug;19(8):964-6. doi: 10.1038/nm.3299. No abstract available.

PMID:
23921738
10.

Acute kidney injury and its association with in-hospital mortality among children with acute infections.

Imani PD, Odiit A, Hingorani SR, Weiss NS, Eddy AA.

Pediatr Nephrol. 2013 Nov;28(11):2199-206. doi: 10.1007/s00467-013-2544-2. Epub 2013 Jul 20.

PMID:
23872929
11.

Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology.

Williams AW, Dwyer AC, Eddy AA, Fink JC, Jaber BL, Linas SL, Michael B, O'Hare AM, Schaefer HM, Shaffer RN, Trachtman H, Weiner DE, Falk AR; American Society of Nephrology Quality, and Patient Safety Task Force.

Clin J Am Soc Nephrol. 2012 Oct;7(10):1664-72. doi: 10.2215/CJN.04970512. Epub 2012 Sep 13.

12.

Vascular endothelial cadherin modulates renal interstitial fibrosis.

Yamaguchi I, Tchao BN, Burger ML, Yamada M, Hyodo T, Giampietro C, Eddy AA.

Nephron Exp Nephrol. 2012;120(1):e20-31. doi: 10.1159/000332026. Epub 2011 Nov 25.

13.

Mannose receptor 2 attenuates renal fibrosis.

López-Guisa JM, Cai X, Collins SJ, Yamaguchi I, Okamura DM, Bugge TH, Isacke CM, Emson CL, Turner SM, Shankland SJ, Eddy AA.

J Am Soc Nephrol. 2012 Feb;23(2):236-51. doi: 10.1681/ASN.2011030310. Epub 2011 Nov 17.

14.

Albumin-induced apoptosis of glomerular parietal epithelial cells is modulated by extracellular signal-regulated kinase 1/2.

Chang AM, Ohse T, Krofft RD, Wu JS, Eddy AA, Pippin JW, Shankland SJ.

Nephrol Dial Transplant. 2012 Apr;27(4):1330-43. doi: 10.1093/ndt/gfr483. Epub 2011 Sep 5.

15.

The TGF-β route to renal fibrosis is not linear: the miR-21 viaduct.

Eddy AA.

J Am Soc Nephrol. 2011 Sep;22(9):1573-5. doi: 10.1681/ASN.2011070698. Epub 2011 Aug 11. No abstract available.

16.

Investigating mechanisms of chronic kidney disease in mouse models.

Eddy AA, López-Guisa JM, Okamura DM, Yamaguchi I.

Pediatr Nephrol. 2012 Aug;27(8):1233-47. doi: 10.1007/s00467-011-1938-2. Epub 2011 Jun 22. Review.

17.

Scraping fibrosis: UMODulating renal fibrosis.

Eddy AA.

Nat Med. 2011 May;17(5):553-5. doi: 10.1038/nm0511-553. Review. No abstract available.

PMID:
21546974
18.

Vitronectin accumulates in the interstitium but minimally impacts fibrogenesis in experimental chronic kidney disease.

López-Guisa JM, Rassa AC, Cai X, Collins SJ, Eddy AA.

Am J Physiol Renal Physiol. 2011 May;300(5):F1244-54. doi: 10.1152/ajprenal.00701.2010. Epub 2011 Jan 26.

19.

Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis.

Okamura DM, Pasichnyk K, Lopez-Guisa JM, Collins S, Hsu DK, Liu FT, Eddy AA.

Am J Physiol Renal Physiol. 2011 Jan;300(1):F245-53. doi: 10.1152/ajprenal.00326.2010. Epub 2010 Oct 20.

20.

Nicotinic acetylcholine receptor α1 promotes calpain-1 activation and macrophage inflammation in hypercholesterolemic nephropathy.

Zhang G, Thomas AL, Marshall AL, Kernan KA, Su Y, Zheng Y, Takano J, Saido TC, Eddy AA.

Lab Invest. 2011 Jan;91(1):106-23. doi: 10.1038/labinvest.2010.135. Epub 2010 Jul 26.

21.

A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis.

Zhang G, Kernan KA, Thomas A, Collins S, Song Y, Li L, Zhu W, Leboeuf RC, Eddy AA.

J Biol Chem. 2009 Oct 16;284(42):29050-64. doi: 10.1074/jbc.M109.010249. Epub 2009 Aug 18.

22.

Serine proteases, inhibitors and receptors in renal fibrosis.

Eddy AA.

Thromb Haemost. 2009 Apr;101(4):656-64. Review.

23.

CD36 regulates oxidative stress and inflammation in hypercholesterolemic CKD.

Okamura DM, Pennathur S, Pasichnyk K, López-Guisa JM, Collins S, Febbraio M, Heinecke J, Eddy AA.

J Am Soc Nephrol. 2009 Mar;20(3):495-505. doi: 10.1681/ASN.2008010009. Epub 2009 Feb 11.

24.

Macrophage diversity in renal injury and repair.

Ricardo SD, van Goor H, Eddy AA.

J Clin Invest. 2008 Nov;118(11):3522-30. doi: 10.1172/JCI36150. Review.

25.

Urokinase and its receptors in chronic kidney disease.

Zhang G, Eddy AA.

Front Biosci. 2008 May 1;13:5462-78. Review.

26.
27.

Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy.

Tang SC, Leung JC, Chan LY, Eddy AA, Lai KN.

Kidney Int. 2008 Feb;73(3):288-99. Epub 2007 Nov 21.

28.

Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury.

Okamura DM, López-Guisa JM, Koelsch K, Collins S, Eddy AA.

Am J Physiol Renal Physiol. 2007 Aug;293(2):F575-85. Epub 2007 May 30.

29.

Endogenous urokinase lacks antifibrotic activity during progressive renal injury.

Yamaguchi I, Lopez-Guisa JM, Cai X, Collins SJ, Okamura DM, Eddy AA.

Am J Physiol Renal Physiol. 2007 Jul;293(1):F12-9. Epub 2007 Mar 13.

30.

Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals.

Zhang G, Kernan KA, Collins SJ, Cai X, López-Guisa JM, Degen JL, Shvil Y, Eddy AA.

J Am Soc Nephrol. 2007 Mar;18(3):846-59. Epub 2007 Jan 31.

31.

Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action.

Eddy AA, Fogo AB.

J Am Soc Nephrol. 2006 Nov;17(11):2999-3012. Epub 2006 Oct 11. Review. No abstract available.

32.

Chronic kidney disease progression.

Eddy AA, Neilson EG.

J Am Soc Nephrol. 2006 Nov;17(11):2964-6. Epub 2006 Oct 11. No abstract available.

33.

Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice.

Collins SJ, Alexander SL, Lopez-Guisa JM, Cai X, Maruvada R, Chua SC, Zhang G, Okamura DM, Matsuo S, Eddy AA.

Nephron Exp Nephrol. 2006;104(1):e23-34. Epub 2006 May 1.

PMID:
16735799
34.

Ramping up endogenous defences against chronic kidney disease.

Eddy AA.

Nephrol Dial Transplant. 2006 May;21(5):1174-7. Epub 2006 Mar 30. No abstract available.

PMID:
16574685
35.

Global gene expression profiling reveals widespread yet distinctive translational responses to different eukaryotic translation initiation factor 2B-targeting stress pathways.

Smirnova JB, Selley JN, Sanchez-Cabo F, Carroll K, Eddy AA, McCarthy JE, Hubbard SJ, Pavitt GD, Grant CM, Ashe MP.

Mol Cell Biol. 2005 Nov;25(21):9340-9.

36.

Progression in chronic kidney disease.

Eddy AA.

Adv Chronic Kidney Dis. 2005 Oct;12(4):353-65. Review.

PMID:
16198274
37.

Can renal fibrosis be reversed?

Eddy AA.

Pediatr Nephrol. 2005 Oct;20(10):1369-75. Epub 2005 Jun 10. Review.

PMID:
15947978
38.

Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.

Matsuo S, López-Guisa JM, Cai X, Okamura DM, Alpers CE, Bumgarner RE, Peters MA, Zhang G, Eddy AA.

Kidney Int. 2005 Jun;67(6):2221-38. Erratum in: Kidney Int. 2005 Aug;68(2):910.

39.

Why is proteinuria an ominous biomarker of progressive kidney disease?

Zandi-Nejad K, Eddy AA, Glassock RJ, Brenner BM.

Kidney Int Suppl. 2004 Nov;(92):S76-89. Review.

40.

Exogenous bone morphogenetic protein-7 fails to attenuate renal fibrosis in rats with overload proteinuria.

Ikeda Y, Jung YO, Kim H, Oda T, López-Guisa J, Maruvada R, Diamond DL, Martin KJ, Wing D, Cai X, Eddy AA.

Nephron Exp Nephrol. 2004;97(4):e123-35.

PMID:
15331933
41.
42.

Expression of nephrin in acquired forms of nephrotic syndrome in childhood.

Hingorani SR, Finn LS, Kowalewska J, McDonald RA, Eddy AA.

Pediatr Nephrol. 2004 Mar;19(3):300-5. Epub 2004 Jan 28.

PMID:
14747939
43.

Proteinuria and interstitial injury.

Eddy AA.

Nephrol Dial Transplant. 2004 Feb;19(2):277-81. No abstract available.

PMID:
14736944
44.

Nephrotic syndrome in childhood.

Eddy AA, Symons JM.

Lancet. 2003 Aug 23;362(9384):629-39. Review.

PMID:
12944064
45.

Urokinase receptor deficiency accelerates renal fibrosis in obstructive nephropathy.

Zhang G, Kim H, Cai X, López-Guisa JM, Alpers CE, Liu Y, Carmeliet P, Eddy AA.

J Am Soc Nephrol. 2003 May;14(5):1254-71.

46.

Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy.

Zhang G, Kim H, Cai X, Lopez-Guisa JM, Carmeliet P, Eddy AA.

J Am Soc Nephrol. 2003 May;14(5):1234-53.

47.

An introduction to frontiers in nephrology.

Eddy AA, Couser WG.

J Am Soc Nephrol. 2002 Aug;13(8):2185. No abstract available.

48.

Plasminogen activator inhibitor-1 and the kidney.

Eddy AA.

Am J Physiol Renal Physiol. 2002 Aug;283(2):F209-20. Review.

49.

PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction.

Oda T, Jung YO, Kim HS, Cai X, López-Guisa JM, Ikeda Y, Eddy AA.

Kidney Int. 2001 Aug;60(2):587-96.

50.

Mast cells find their way to the kidney.

Eddy AA.

Kidney Int. 2001 Jul;60(1):375-7. No abstract available. Erratum in: Kidney Int 2001 Sep;60(3):1216-7.

Supplemental Content

Support Center